R&D Spending Showdown: Eli Lilly and Company vs AbbVie Inc.

Eli Lilly vs. AbbVie: A Decade of R&D Investment

__timestampAbbVie Inc.Eli Lilly and Company
Wednesday, January 1, 201432970000004733600000
Thursday, January 1, 201542850000004796400000
Friday, January 1, 201643660000005243900000
Sunday, January 1, 201749820000005281800000
Monday, January 1, 2018103290000005051200000
Tuesday, January 1, 201964070000005595000000
Wednesday, January 1, 202065570000006085700000
Friday, January 1, 202170840000007025900000
Saturday, January 1, 202265100000007190800000
Sunday, January 1, 202384530000009313400000
Monday, January 1, 2024014271000000
Loading chart...

Igniting the spark of knowledge

R&D Spending Trends: A Decade of Innovation

In the competitive landscape of pharmaceutical giants, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, Eli Lilly and Company and AbbVie Inc. have been at the forefront of this race. From 2014 to 2023, Eli Lilly's R&D expenses surged by nearly 97%, peaking in 2023 with a remarkable $9.3 billion. Meanwhile, AbbVie, despite a significant 156% increase in R&D spending, reached its highest in 2018 with $10.3 billion.

A Closer Look at the Numbers

Eli Lilly consistently increased its R&D investment, particularly from 2020 onwards, reflecting a strategic focus on innovation. AbbVie, on the other hand, experienced a notable spike in 2018, followed by a steady investment pattern. This financial commitment underscores the companies' dedication to pioneering new treatments and maintaining a competitive edge in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025